Scott is the head of patient advocacy at Myeloma UK and chair of the CMAC. Scott leads Myeloma UKs health policy activities, including health technology assessment engagement with NICE, the NHS and the pharmaceutical industry. Key policy workstreams include advocating for all people living with myeloma to have access to early diagnosis pathways, and access to the best treatments delivering optimal health and quality of life outcomes. Scott is the chair of CMAC, a coalition of 25 member charities, which include major funders of research, representing millions of patients with lived experience in the UK. CMAC works to find long-term solutions to equitable adoption of new medicines in the NHSE and seeks to overcome the challenges that delay or prevent patient access to innovative medicines.

Scott has been involved in access to medicine advocacy for over 25 years leading joint working partnerships with patient organisations, governments, World Health Organization and United Nations organisations, national health services and the pharmaceutical industry across the UK, Europe, and directed global health programmes. He has a PhD in molecular biology from the University of Aberdeen and held senior global and UK roles in government affairs and patient advocacy with the pharmaceutical industry, including GSK, ViiV Healthcare and Gilead.